Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
| 适应症 | Human Immunodeficiency Virus, HBV, Fibrosis, Liver, Cirrhosis, Liver |
|---|---|
| 分期 | 不适用 |
| 申办方 | University of Alabama at Birmingham |
| 状态 | 已完成 |
| 受试者人数 | 349 人 |
| 干预（药物） | Anti-HIV Agents |
| 开始日期 | 2015年10月 |
| 完成日期 | 2026年5月28日 |
| 结果公布日 | 2026年7月2日 |
摘要
A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to identify the risk factors for major endpoints of interest, including HCC and HBV functional cure. This cohort will also create a pool of potential participants for in-depth mechanistic studies and clinical trials of novel HBV cure drugs.
Reduction in Liver Fibrosis Stage
| HBV/HIV Cohort | 46 Participants |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)